Minimally Clinical Important Differences of Hemifacial Spasm Score-30 (HFS-30) and Hemifacial Spasm Score-7 (HFS-7) for Patients with Hemifacial spasm
Objective: We aimed to estimate the MCIDs of HFS-30 and HFS-7, and factors associated with the MCID along with baseline and change score of HFS-30…Developing a Supportive Care and Wellness Program for Parkinson’s Patients
Objective: To review the literature and framework of the Supportive Care and Wellness Program at Weill Cornell Parkinson's Disease & Movement Disorders Institute for people…Assessing Barriers to Advance Care Planning in Parkinson’s Disease Within a Cuban-American Population
Objective: Determine attitudes toward advance care planning among Cuban-American people with Parkinson’s disease (PWP). Background: Advance care planning (ACP) is a process that allows individuals…Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide
Objective: An innovative, multi-study Phase 3 program to definitively assess safety and efficacy of ulixacaltamide in essential tremor (ET). Background: Phase 2 studies of ulixacaltamide,…Correlation Between Sleep and Quality of Life in People With Parkinson’s Disease Treated With Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa
Objective: To assess the correlation between sleep and quality of life (QoL) in people with Parkinson’s disease (PwP) receiving either oral levodopa/carbidopa immediate-release (LD/CD-IR) tablets…Clinical and Safety Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control – Real-World, USA Experience
Objective: Here, we present preliminary outcomes from an on-going, prospective, multicenter outcomes registry conducted in the USA consisting of patients implanted with directional Deep Brain…The 201 Trial in Untreated Parkinson’s Disease
Objective: To evalute the safety, tolerability, clinical benefit and protein pathology status following risvodetinib (IkT-148009) treatment in participants with untreated Parkinson's disease. Background: RIsvodetinib is…Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension
Objective: Evaluate long-term motor symptom control and improvement in quality of life (QoL) with foslevodopa/foscarbidopa (LDp/CDp) compared with baseline (BL) values from the parent study…Parkinson’s Progression Markers Initiative (PPMI): Investigating Biomarker Driven PD Progression
Objective: PPMI is a longitudinal, observational study enrolling PD participants, individuals at risk for PD, and healthy controls (HCs). The study investigates clinical, imaging, genetic…Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism
Objective: To evaluate recruitment, eligibility and characteristics of clinic referred vs self-referred patients in the ongoing Trial of Parkinson’s and Zoledronate (TOPAZ, NCT03924414) Background: People…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 181
- Next Page »